1. Continuous subcutaneous levodopa-carbidopa infusion for Parkinson's disease.
- Author
-
Moes HR, Buskens E, and van Laar T
- Subjects
- Humans, Levodopa administration & dosage, Parkinson Disease drug therapy, Carbidopa administration & dosage, Antiparkinson Agents administration & dosage, Infusions, Subcutaneous, Drug Combinations
- Abstract
Competing Interests: HRM received a research grant from the University Medical Center Groningen (GR-AGIKO 18-02); received a clinical fellowship grant from the European Academy of Neurology (2022); received a speaker fee from Centrafarm and Britannia; is an unpaid Data Safety Monitoring Board member of the GRoningen Early-PD Ambroxol Treatment trial (NCT05830396); and received the 2023 talent prize from ParkinsonNL. EB received research grants from Zorg Onderzoek Medische Wetenschappen and Nederlandse organisatie voor Wetenschappelijk Onderzoek for projects on clustered living in elderly people and innovation in dementia care; and serves on advisory boards for the nursing home ZuidOostZorg, Accare (child psychiatry), and 113 suicide prevention. TvL received consulting fees from AbbVie and Britannia Pharm; and received speaker fees from Eurocept, Genilec, Britannia Pharm, and AbbVie.
- Published
- 2024
- Full Text
- View/download PDF